Fungal infections in bone marrow transplant recipients

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 3, 2006, Pages 307-315

  Raman, Tuhina ^a   Marik, Paul E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Aspergillus; Bone marrow transplant; Candidemia; Immmunocompromised

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CASPOFUNGIN; DEXAMETHASONE; ECHINOCANDIN; EFAVIRENZ; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MICAFUNGIN; NELFINAVIR; NEVIRAPINE; PHENYTOIN; POSACONAZOLE; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RAVUCONAZOLE; RIFABUTIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STEROID; UNINDEXED DRUG; VORICONAZOLE;

ANEMIA; ASPERGILLOSIS; ASPERGILLUS; BLOOD TOXICITY; BLURRED VISION; BONE MARROW TRANSPLANTATION; CANDIDA; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; FACE EDEMA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; LIVER TOXICITY; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PHLEBITIS; PHOTOPHOBIA; PHOTOSENSITIVITY; POLYMERASE CHAIN REACTION; PRURITUS; REVIEW; RISK FACTOR; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VISUAL DISORDER; VOMITING;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PEPTIDES, CYCLIC; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS; TRIAZOLES;

EID: 33144490306     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.3.307     Document Type: Review

References (46)

1. MARTINO R, SUBIRA M, ROVIRA M et al.: Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br. J. Haematol. (2002) 116:475-482.
2. HUARINGA AJ, LEYVA FJ, GIRALT SA et al.: Outcome of bone marrow transplantation patients requiring mechanical ventilation. Crit. Care Med. (2000) 28:1014-1017.
3. BACH PB, SCHRAG D, NIERMAN DM et al.: Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. Blood (2001) 98:3234-3240.
4. MORGAN J, WANNEMUEHLER KA, MARR KA et al.: Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med. Mycol. (2005) 43(Suppl. 1):S49-S58.
5. NYILASI I, PAPP T, TAKO M et al.: Iron gathering of opportunistic pathogenic fungi. A mini review. Acta Microbiol. Immunol. Hung. (2005) 52:185-197.
6. BELLOCCHIO S, BOZZA S, MONTAGNOLI C et al.: Immunity to Aspergillus fumigatus: the basis for immunotherapy and vaccination. Med. Mycol. (2005) 43(Suppl. 1):S181-S188.
7. LEMAITRE B, NICOLAS E, MICHAUT L et al.: The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell (1996) 86:973-983.
8. UNDERHILL DM, OZINSKY A, HAJJAR AM et al.: The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature (1999) 401:811-815.
9. BLEASE K, KUNKEL SL, HOGABOAM CM: IL-18 modulates chronic fungal asthma in a murine model; putative involvement of Toll-like receptor-2. Inflamm. Res. (2001) 50:552-560.
10. DE ROSA FG, SHAZ D, CAMPAGNA AC et al.: Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect. Control Hosp. Epidemiol. (2003) 24:477-482.
11. WARRIS A, BJORNEKLETT A, GAUSTAD P: Invasive pulmonary aspergillosis associated with infliximab therapy. N. Engl. J. Med. (2001) 344:1099-1100.
12. BALLOY V, SI-TAHAR M, TAKEUCHI O et al.: Involvement of Toll-like receptor 2 in experimental invasive pulmonary aspergillosis. Inject. Immun. (2005) 73:5420-5425.
13. CENCI E, MENCACCI A, FE D'OSTIANI C et al.: Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J. Infect. Dis. (1998) 178:1750-1760.
14. MEHRAD B, STRIETER RM, MOORE TA et al.: CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis. J. Immunol. (1999) 163:6086-6094.
15. GOLAN Y: Overview of transplant mycology. Am. J. Health Syst. Pharm. (2005) 62:S17-S21.
16. KOLDEHOFF M, ZAKRZEWSKI JL: Modern management of respiratory failure due to pulmonary mycoses following allogeneic hematopoietic stem-cell transplantation. Am. J. Hematol. (2005) 79:158-163.
17. KOJIMA R, TATEISHI U, KAMI M et al.: Chest computed tomography of late invasive aspergillosis after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. (2005) 11:506-511.
18. MCLINTOCK LA, JONES BL: Advances in the molecular and serological diagnosis of invasive fungal infection in haematooncology patients. Br. J. Haematol. (2004) 126:289-297.
19. BECKER MJ, LUGTENBURG EJ, CORNELISSEN JJ et al.: Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br. J. Haematol. (2003) 121:448-457.
20. SPIESS B, BUCHHEIDT D, BAUST C et al.: Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients. J. Clin. Microbiol. (2003) 41:1811-1818.
21. KONTOYIANNIS DP, REDDY BT, TORRES HA et al.: Pulmonary candidiasis in patients with cancer: an autopsy study. Clin. Infect. Dis. (2002) 34:400-403.
22. HERBRECHT R, LETSCHER-BRU V, OPREA C et al.: Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol. (2002) 20:1898-1906.
23. ROHRLICH P, SARFATI J, MARIANI P et al.: Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. Pediatr. Infect. Dis. J. (1996) 15:232-237.
24. FRANCIS P, LEE JW, HOFFMAN A et al.: Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J. Infect. Dis. (1994) 169:356-368.
25. VERWEIJ PE, MEIS JF: Microbiological diagnosis of invasive fungal infections in transplant recipients. Transpl. Infect. Dis. (2000) 2:80-87.
26. MITSUTAKE K, MIYAZAKI T, TASHIRO T et al.: Enolase antigen, mannan antigen, Cand-Tec antigen, and β-glucan in patients with candidemia. J. Clin. Microbiol. (1996) 34:1918-1921.
27. EINSELE H, HEBART H, ROLLER G et al.: Detection and identification of fungal pathogens in blood by using molecular probes. J. Clin. Microbiol. (1997) 35:1353-1360.
28. CENTERS FOR DISEASE CONTROL AND PREVENTION; INFECTIOUS DISEASE SOCIETY OF AMERICA; AMERICAN SOCIETY OF BLOOD AND MARROW TRANSPLANTATION: Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm. Rep. (2000) 49:1-125, CE1-CE7.
29. HUGHES WT, ARMSTRONG D, BODEY GP et al.: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. (2002) 34:730-751.
30. PAPPAS PG, REX JH, SOBEL JD et al.: Guidelines for treatment of candidiasis. Clin. Infect. Dis. (2004) 38:161-189.
31. SLAVIN MA, OSBORNE B, ADAMS R et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantatio - a prospective, randomized, double-blind study. J. Infect. Dis. (1995) 171:1545-1552.
32. WINSTON DJ, MAZIARZ RT, CHANDRASEKAR PH et al.: Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann. Intern. Med. (2003) 138:705-713.
33. MARR KA, CRIPPA F, LEISENRING W et al.: Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood (2004) 103:1527-1533.
34. MCLINTOCK LA, JORDANIDES NE, ALLAN EK et al.: The use of a risk group stratification in the management of invasive fungal infection: a prospective validation. Br. J. Haematol. (2004) 124:403-404.
35. PRENTICE HG, KIBBLER CC, PRENTICE AG: Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br. J. Haematol. (2000) 110:273-284.
36. HAMZA NS, GHANNOUM MA, LAZARUS HM: Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. (2004) 34:377-389.
37. BOW EJ: Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients. Med. Mycol. (2005) 43(Suppl. 1):S277-S287.
38. MARR KA, BOWDEN RA: Fungal infections in patients undergoing blood and marrow transplantation. Transpl. Infect. Dis. (1999) 1:237-246.
39. WALSH TJ, PAPPAS P, WINSTON DJ et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. (2002) 346:225-234.
40. DENNING DW, RIBAUD P, MILPIED N et al.: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. (2002) 34:563-571.
41. HERBRECHT R, DENNING DW, PATTERSON TF et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. (2002) 347:408-415.
42. MAERTENS J, RAAD I, PETRIKKOS G et al.: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. (2004) 39:1563-1571.
43. PHILLIPS P, SHAFRAN S, GARBER G et al.: Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur. J. Clin. Microbiol. Infect. Dis. (1997) 16:337-345.
44. REX JH, PAPPAS PG, KARCHMER AW et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. (2003) 36:1221-1228.
45. MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. (2002) 347:2020-2029.
46. WALSH TJ, ADAMSON PC, SEIBEL NL et al.: Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. (2005) 49:4536-4545.